甘肃医药2026，Vol.45Issue(4)：301-305,5.DOI:10.15975/j.cnki.1004-2725.2026.04.003
MSS/pMMR大肠癌的免疫联合治疗研究进展
Research progress on immune combination therapy for MSS/pMMR advanced colorectal cancer
摘要
Abstract
In recent years,immune checkpoint inhibitors(ICIs)have developed rapidly in the treatment of many malignant solid tumors.Studies show that colorectal cancer(CRC),the third most common malignant tumor globally,yields favorable therapeutic responses to ICIs only in patients with metastatic colorectal cancer(mCRC)with microsatellite instability-high/deficient mismatch repair(MSI-H/dMMR),which ac-counts for only about 5%of cases.In contrast,the vast majority of patients with advanced CRC with microsatellite stability/mismatch repair pro-ficiency(MSS/pMMR)can hardly benefit from single-agent ICI therapy.Therefore,how to improve the efficacy of ICIs in the treatment of ad-vanced MSS/pMMR colorectal cancer has become a current research hotspot.This article reviews the combination modes,potential mechanisms and existing progress of ICIs in the treatment of MSS/pMMR CRC.关键词
结直肠肿瘤/免疫检查点抑制剂/微卫星稳定/错配修复完整/免疫治疗Key words
colorectal cancer/immune checkpoint inhibitors/microsatellite stability/complete mismatch repair/immunotherapy分类
医药卫生引用本文复制引用
周霞东,张发展,梁佳,王海云,张昭,任维维..MSS/pMMR大肠癌的免疫联合治疗研究进展[J].甘肃医药,2026,45(4):301-305,5.基金项目
甘肃省卫生健康行业科技创新重大科研项目(编号:GSWSQNPY2024-08) （编号:GSWSQNPY2024-08）
